2058 related articles for article (PubMed ID: 28057361)
1. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial.
Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB
J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis.
Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K
N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787
[TBL] [Abstract][Full Text] [Related]
4. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies.
Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA
Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
Griffiths CEM; Papp KA; Kimball AB; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
J Drugs Dermatol; 2018 Aug; 17(8):826-832. PubMed ID: 30124721
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials.
Foley P; Gordon K; Griffiths CEM; Wasfi Y; Randazzo B; Song M; Li S; Shen YK; Blauvelt A
JAMA Dermatol; 2018 Jun; 154(6):676-683. PubMed ID: 29799960
[TBL] [Abstract][Full Text] [Related]
7. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
Al-Salama ZT; Scott LJ
Am J Clin Dermatol; 2018 Dec; 19(6):907-918. PubMed ID: 30467781
[TBL] [Abstract][Full Text] [Related]
8. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study.
Gordon KB; Armstrong AW; Han C; Foley P; Song M; Wasfi Y; You Y; Shen YK; Reich K
J Eur Acad Dermatol Venereol; 2018 Nov; 32(11):1940-1949. PubMed ID: 29706008
[TBL] [Abstract][Full Text] [Related]
9. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study.
Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H
J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis:
Youn SW; Yu DY; Kim TY; Kim BS; Lee SC; Lee JH; Choe YB; Lee JH; Choi JH; Roh JY; Jo SJ; Lee ES; Shin MK; Lee MG; Jiang J; Lee Y
J Dermatolog Treat; 2022 Feb; 33(1):535-541. PubMed ID: 32419536
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study.
Reich K; Armstrong AW; Foley P; Song M; Miller M; Shen YK; You Y; Han C; Gordon KB
Am J Clin Dermatol; 2020 Dec; 21(6):881-890. PubMed ID: 32910434
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Reich K; Griffiths CEM; Gordon KB; Papp KA; Song M; Randazzo B; Li S; Shen YK; Han C; Kimball AB; Armstrong AW; Foley P; Blauvelt A
J Am Acad Dermatol; 2020 Apr; 82(4):936-945. PubMed ID: 31809827
[TBL] [Abstract][Full Text] [Related]
13. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial.
Papp KA; Blauvelt A; Kimball AB; Han C; Randazzo B; Wasfi Y; Shen YK; Li S; Griffiths CEM
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1515-1522. PubMed ID: 29512196
[TBL] [Abstract][Full Text] [Related]
15. Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2.
Puig L; Wu JJ; Gooderham MJ; You Y; Shen YK; Randazzo B; Kerdel F
J Dermatolog Treat; 2021 Aug; 32(5):484-491. PubMed ID: 31613178
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial.
Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L
Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018
[TBL] [Abstract][Full Text] [Related]
17. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study.
Gordon KB; Armstrong AW; Foley P; Song M; Shen YK; Li S; Muñoz-Elías EJ; Branigan P; Liu X; Reich K
J Invest Dermatol; 2019 Dec; 139(12):2437-2446.e1. PubMed ID: 31207232
[TBL] [Abstract][Full Text] [Related]
18. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2.
Reich K; Gordon KB; Strober BE; Armstrong AW; Miller M; Shen YK; You Y; Han C; Yang YW; Foley P; Griffiths CEM
Br J Dermatol; 2021 Dec; 185(6):1146-1159. PubMed ID: 34105767
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Guselkumab, an Anti-interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis: A Randomized Clinical Trial.
Terui T; Kobayashi S; Okubo Y; Murakami M; Hirose K; Kubo H
JAMA Dermatol; 2018 Mar; 154(3):309-316. PubMed ID: 29417135
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
Gordon KB; Blauvelt A; Foley P; Song M; Wasfi Y; Randazzo B; Shen YK; You Y; Griffiths CEM
Br J Dermatol; 2018 Jan; 178(1):132-139. PubMed ID: 28940259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
